Compare AbCellera Biologics Inc (ABCL) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Eaton Corporation plc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Eaton Corporation plc trades at $399.21 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 65.4× AbCellera Biologics Inc's market cap, and Eaton Corporation plc pays a 1.11% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ETN | |
|---|---|---|
Market Cap | $2.35B | $153.64B |
Sector | Health | Technology |
52-Week High | $8.12 | $435.78 |
52-Week Low | $2.78 | $315.82 |
Enterprise Value | $1.99B | $174.72B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.
Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
